Malcolm T. Rutledge

Malcolm T. Rutledge

Auto-generated profile, based on publicly available information

Malcolm T. Rutledge

Department of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand; HeartOtago, University of Otago, Dunedin, New Zealand

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
ESEleni Siakkou
Eleni Siakkou
MRMalcolm T. Rutledge
Malcolm T. Rutledge
SWSigurd M. Wilbanks
Sigurd M. Wilbanks
GJGuy N. L. Jameson
Guy N. L. Jameson

1 March 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ESEmma Spencer
Emma Spencer
EDEdward J. Dale
Edward J. Dale
AGAimée L. Gommans
Aimée L. Gommans
MRMalcolm T. Rutledge
Malcolm T. Rutledge
CVChristine T. Vo
Christine T. Vo
Joel TyndallJoel Tyndall
Joel Tyndall

1 October 2023 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
HSHalima Siddiqui
Halima Siddiqui
NDNikita Deo
Nikita Deo
MRMalcolm T. Rutledge
Malcolm T. Rutledge
MWMichael J.A. Williams
Michael J.A. Williams
GRGregory Redpath
Gregory Redpath
SMSally P.A. McCormick
Sally P.A. McCormick
BACKGROUND: High levels of Lp(a) (lipoprotein(a)) are associated with multiple forms of cardiovascular disease. Lp(a) consists of an apoB 100 -containing particle attached to the plasminogen homologue apo(a). The pathways for Lp(a) clearance are not well understood. We previously discovered that the plasminogen receptor PlgRKT (plasminogen receptor with a C-terminal lysine) promoted Lp(a) uptake in liver cells. Here, we aimed to further define the role of PlgRKT and to investigate the role of 2 other plasminogen receptors, annexin A2 and S100A10 (S100 calcium-binding protein A10) in the endocytosis of Lp(a). METHODS: Human hepatocellular carcinoma (HepG2) cells and haploid human fibroblast-like (HAP1) cells were used for overexpression and knockout of plasminogen receptors. The uptake of Lp(a), LDL (low-density lipoprotein), apo(a), and endocytic cargos was visualized and quantified by confocal microscopy and Western blotting. RESULTS: The uptake of both Lp(a) and apo(a), but not LDL, was significantly increased in HepG2 and HAP1 cells overexpressing PlgRKT, annexin A2, or S100A10. Conversely, Lp(a) and apo(a), but not LDL, uptake was significantly reduced in HAP1 cells in which PlgRKT and S100A10 were knocked out. Surface binding studies in HepG2 cells showed that overexpression of PlgRKT, but not annexin A2 or S100A10, increased Lp(a) and apo(a) plasma membrane binding. Annexin A2 and S100A10, on the other hand, appeared to regulate macropinocytosis with both proteins significantly increasing the uptake of the macropinocytosis marker dextran when overexpressed in HepG2 and HAP1 cells and knockout of S100A10 significantly reducing dextran uptake. Bringing these observations together, we tested the effect of a PI3K (phosphoinositide-3-kinase) inhibitor, known to inhibit macropinocytosis, on Lp(a) uptake. Results showed a concentration-dependent reduction confirming that Lp(a) uptake was indeed mediated by macropinocytosis. CONCLUSIONS: These findings uncover a novel pathway for Lp(a) endocytosis involving multiple plasminogen receptors that enhance surface binding and stimulate macropinocytosis of Lp(a). Although the findings were produced in cell culture models that have limitations, they could have clinical relevance since drugs that inhibit macropinocytosis are in clinical use, that is, the PI3K inhibitors for cancer therapy and some antidepressant compounds.

29 August 2012 in Acta Crystallographica Section F Structural Biology and Crystallization Communications
Verified
Journal Article
Open access
PDF file
Joel TyndallJoel Tyndall
Joel Tyndall
HLHongqi Lue
Hongqi Lue
MRMalcolm T. Rutledge
Malcolm T. Rutledge
JBJürgen Bernhagen
Jürgen Bernhagen
Mark B. HamptonMark B. Hampton
Mark B. Hampton
SWSigurd M. Wilbanks
Sigurd M. Wilbanks
Macrophage migration inhibitory factor is irreversibly inhibited via covalent modification by phenethyl isothiocyanate, a naturally occurring compound with anti-inflammatory and anticancer properties. The structure of the modified protein obtained from X-ray diffraction data to 1.64 Å resolution is presented. The inhibitor sits within a deep hydrophobic pocket between subunits of the homotrimer and is highly ordered. The secondary structure of macrophage migratory inhibitory factor is unchanged by this modification, but there are significant rearrangements, including of the side-chain position of Tyr37 and the main chain of residues 31-34. These changes may explain the decreased binding of the modified protein to the receptor CD74. Together with the pocket, the areas of conformational change define specific targets for the design of more selective and potent inhibitors as potential therapeutics.

13 September 2024 in ChemMedChem
Verified
Journal Article
Open access
LPLohitha Putha
Lohitha Putha
LKLiang K. Kok
Liang K. Kok
Matthias FellnerMatthias Fellner
Matthias Fellner
MRMalcolm T. Rutledge
Malcolm T. Rutledge
AGAllan B. Gamble
Allan B. Gamble
Joel TyndallJoel Tyndall
Joel Tyndall
Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that has roles in innate and adaptive human immune responses, as well as inflammation. MIF exerts its biological activity by binding to the cell surface receptor CD74 as well as intracellular signalling proteins. MIF also possesses keto‐enol tautomerase activity. Inhibition of the tautomerase activity has been associated with loss of biological activity of MIF and a potential anticancer target. Isothiocyanates (ITCs) are a class of compounds present in cruciferous vegetables that inhibit the MIF tautomerase activity via covalent modification of the N‐terminal proline. A range of substituted ITCs featuring benzyl, phenethyl and phenyl propyl isothiocyanates were designed, synthesised and tested to determine any structure activity relationship for inhibiting MIF. Crystal structures of covalent compounds 8 and 9 in complex with rhMIF revealed key hydrogen bonding and edge‐to‐face π stacking interactions. Compound 9 and 11 with sub micromolar activity were tested in the NCI60 cancer cell lines panel. Both compounds showed tissue‐specific reduced growth in colon and renal cancer cell lines, while one of these showed potent, dose‐dependent inhibition of growth against all seven colon cancer cell lines (GI50<2.5 μM) and all eight renal cancer cell lines (GI50<2.2 μM).

26 August 2020 in New Zealand Journal of Botany
Verified
Journal Article
Open access
THThomas Neil George Handley
Thomas Neil George Handley
HTHyon-Xhi Tan
Hyon-Xhi Tan
MRMalcolm T. Rutledge
Malcolm T. Rutledge
HBHans Henning Brewitz
Hans Henning Brewitz
Joel TyndallJoel Tyndall
Joel Tyndall
SWSigurd M. Wilbanks
Sigurd M. Wilbanks
A system based on cyanobacterial split inteins, SICLOPPs (Split Intein Circular Ligation of Proteins and Peptides), has been used to synthesise a small natively cyclic plant protein, kalata B1, and cyclised versions of the natively linear therapeutic peptides ziconotide and leconotide. The cyclic versions of these naturally linear peptides include linker sequences between their native termini to allow the correct tertiary structure to form. The native structure of each includes three disulphide bonds characteristic of knottins. Cyclic permutations of leconotide yielded different proportions of correctly spliced product, identifying an optimal splice site and revealing the influence of residues around the splice junction. The rate of splicing was manipulated to facilitate affinity purification prior to intein-mediated removal of the affinity tag.